Do analysts recommend ENTX or ZIVO?

Entera Bio presently has a consensus price target of $9.00, indicating a potential upside of 408.47%. Given Entera Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Entera Bio is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ENTX or ZIVO more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -83.31% -70.83% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer CLNN or ZIVO?

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 439.77%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, CLNN or ZIVO?

ZIVO Bioscience has lower revenue, but higher earnings than Clene. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 393.62 -$26.17M -$3.20 N/A ZIVO Bioscience $15.85K 1,136.89 -$7.78M -$1.71 N/A

Is CLNN or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts rate SCLX or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, SCLX or ZIVO?

ZIVO Bioscience has lower revenue, but higher earnings than Scilex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scilex $30.25M 2.55 -$358.73M -$40.47 N/A ZIVO Bioscience $15.85K 1,136.89 -$7.78M -$1.71 N/A

Is SCLX or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts prefer LFVN or ZIVO?

Lifevantage currently has a consensus target price of $5.00, suggesting a potential downside of 19.42%. Given Lifevantage's stronger consensus rating and higher probable upside, equities research analysts plainly believe Lifevantage is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, LFVN or ZIVO?

Lifevantage has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifevantage $228.53M 0.34 $9.81M $0.45 13.79 ZIVO Bioscience $15.85K 1,136.89 -$7.78M -$1.71 N/A

Do analysts recommend ZIVO or HRTX?

Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 481.40%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

ZIVO Bioscience (ZIVO) Competitors

$4.34 -0.49 (-10.13%)

As of 09:30 AM Eastern

Compare

ZIVO vs. ENTX, CLNN, SCLX, LFVN, and HRTX

Should you buy ZIVO Bioscience stock or one of its competitors? MarketBeat compares ZIVO Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZIVO Bioscience include Entera Bio (ENTX), Clene (CLNN), Scilex (SCLX), Lifevantage (LFVN), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does ZIVO Bioscience compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

ZIVO Bioscience has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

Entera Bio has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Entera Bio presently has a consensus price target of $9.00, indicating a potential upside of 408.47%. Given Entera Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Entera Bio is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Entera Bio had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Entera Bio and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 beat Entera Bio's score of -0.10 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Entera Bio	Neutral
ZIVO Bioscience	Neutral

ZIVO Bioscience's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

Entera Bio beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Clene?

Clene (NASDAQ:CLNN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

ZIVO Bioscience has lower revenue, but higher earnings than Clene. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	393.62	-$26.17M	-$3.20	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

In the previous week, Clene had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Clene and 0 mentions for ZIVO Bioscience. Clene's average media sentiment score of 1.13 beat ZIVO Bioscience's score of 0.00 indicating that Clene is being referred to more favorably in the media.

Company	Overall Sentiment
Clene	Positive
ZIVO Bioscience	Neutral

ZIVO Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Clene currently has a consensus price target of $33.25, suggesting a potential upside of 439.77%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

23.3% of Clene shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Clene has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Summary

Clene beats ZIVO Bioscience on 9 of the 15 factors compared between the two stocks.

How does ZIVO Bioscience compare to Scilex?

Scilex (NASDAQ:SCLX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

69.7% of Scilex shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 4.5% of Scilex shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Scilex has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

In the previous week, Scilex had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Scilex and 0 mentions for ZIVO Bioscience. Scilex's average media sentiment score of 0.83 beat ZIVO Bioscience's score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company	Overall Sentiment
Scilex	Positive
ZIVO Bioscience	Neutral

ZIVO Bioscience has lower revenue, but higher earnings than Scilex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.55	-$358.73M	-$40.47	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Summary

Scilex beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does ZIVO Bioscience compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Lifevantage currently has a consensus target price of $5.00, suggesting a potential downside of 19.42%. Given Lifevantage's stronger consensus rating and higher probable upside, equities research analysts plainly believe Lifevantage is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lifevantage has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.79
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

In the previous week, Lifevantage had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Lifevantage and 0 mentions for ZIVO Bioscience. Lifevantage's average media sentiment score of 1.23 beat ZIVO Bioscience's score of 0.00 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Positive
ZIVO Bioscience	Neutral

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lifevantage has a net margin of 2.94% compared to ZIVO Bioscience's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat ZIVO Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Lifevantage has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Summary

Lifevantage beats ZIVO Bioscience on 13 of the 15 factors compared between the two stocks.

How does ZIVO Bioscience compare to Heron Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

ZIVO Bioscience has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

In the previous week, Heron Therapeutics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Heron Therapeutics and 0 mentions for ZIVO Bioscience. Heron Therapeutics' average media sentiment score of 0.56 beat ZIVO Bioscience's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Heron Therapeutics	Positive

Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 481.40%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ZIVO Bioscience has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. ZIVO Bioscience's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

ZIVO Bioscience has higher earnings, but lower revenue than Heron Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A
Heron Therapeutics	$154.90M	0.53	-$20.19M	-$0.18	N/A

Summary

Heron Therapeutics beats ZIVO Bioscience on 10 of the 16 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.02M	$350.61M	$6.78B	$12.65B
Dividend Yield	N/A	N/A	2.68%	8.43%
P/E Ratio	-0.89	N/A	27.13	24.40
Price / Sales	1,136.89	200.02	525.28	91.46
Price / Cash	N/A	22.44	48.59	59.39
Price / Book	-5.36	4.86	10.85	6.33
Net Income	-$7.78M	-$141.03M	$3.59B	$331.45M
7 Day Performance	-17.33%	-3.93%	-1.34%	0.18%
1 Month Performance	17.62%	2.33%	2.96%	-0.72%
1 Year Performance	-67.32%	57.44%	28.93%	20.53%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.34 -10.1%	N/A	-64.2%	$18.02M	$15.85K	N/A	10	Gap Down
ENTX Entera Bio	1.8678 of 5 stars	$1.63 -4.4%	$9.00 +453.8%	-10.0%	$80.10M	$40K	N/A	20	Short Interest Increase
CLNN Clene	3.7028 of 5 stars	$6.20 -0.9%	$33.25 +436.7%	+66.0%	$79.17M	$200K	N/A	100	News Coverage
SCLX Scilex	0.8089 of 5 stars	$9.27 +0.7%	N/A	+38.6%	$78.66M	$33.86M	N/A	80
LFVN Lifevantage	2.9101 of 5 stars	$6.21 -0.6%	$5.00 -19.5%	-49.9%	$78.17M	$228.53M	13.76	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. ENTX, CLNN, SCLX, LFVN, and HRTX

How does ZIVO Bioscience compare to Entera Bio?

Summary

How does ZIVO Bioscience compare to Clene?

Summary

How does ZIVO Bioscience compare to Scilex?

Summary

How does ZIVO Bioscience compare to Lifevantage?

Summary

How does ZIVO Bioscience compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. ENTX, CLNN, SCLX, LFVN, and HRTX

How does ZIVO Bioscience compare to Entera Bio?

Which has higher earnings and valuation, ENTX or ZIVO?

Which has more volatility and risk, ENTX or ZIVO?

Do analysts recommend ENTX or ZIVO?

Do insiders and institutionals have more ownership in ENTX or ZIVO?

Does the media favor ENTX or ZIVO?

Is ENTX or ZIVO more profitable?

Summary

How does ZIVO Bioscience compare to Clene?

Which has stronger earnings and valuation, CLNN or ZIVO?

Does the media favor CLNN or ZIVO?

Is CLNN or ZIVO more profitable?

Do analysts prefer CLNN or ZIVO?

Do insiders & institutionals hold more shares of CLNN or ZIVO?

Which has more volatility & risk, CLNN or ZIVO?

Summary

How does ZIVO Bioscience compare to Scilex?

Do insiders and institutionals hold more shares of SCLX or ZIVO?

Do analysts rate SCLX or ZIVO?

Which has more volatility & risk, SCLX or ZIVO?

Does the media favor SCLX or ZIVO?

Which has stronger valuation & earnings, SCLX or ZIVO?

Is SCLX or ZIVO more profitable?

Summary

How does ZIVO Bioscience compare to Lifevantage?

Do analysts prefer LFVN or ZIVO?

Which has better valuation & earnings, LFVN or ZIVO?

Does the media prefer LFVN or ZIVO?

Do institutionals and insiders hold more shares of LFVN or ZIVO?

Is LFVN or ZIVO more profitable?

Which has more risk and volatility, LFVN or ZIVO?

Summary

How does ZIVO Bioscience compare to Heron Therapeutics?

Which has more risk and volatility, ZIVO or HRTX?

Does the media refer more to ZIVO or HRTX?

Do analysts recommend ZIVO or HRTX?

Do insiders & institutionals hold more shares of ZIVO or HRTX?

Is ZIVO or HRTX more profitable?

Which has better valuation & earnings, ZIVO or HRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools